Medtronic Raises 2027 Forecasts Amid Surge in Heart Device Demand

Medtronic has revised its fiscal 2027 financial forecasts upward, citing robust demand for its heart devices. This adjustment reflects confidence in the company's expanding cardiovascular portfolio and market strategies.

Financial Projections Revised

On Tuesday, Medtronic announced an increase in its expected annual organic revenue growth for fiscal 2027, now projecting a range of 7.25% to 7.75%, up from the previous 6.75% to 7.25%. The lower end of its adjusted per-share profit forecast has also been raised to $5.94, while the upper limit remains at $6.

This optimistic outlook is attributed to the strong performance across Medtronic's business segments, particularly in cardiovascular solutions. Quarterly sales for this segment soared by 19.5% to $3.93 billion, driven by a significant 88% growth in its pulsed field ablation products.

Strategic Investments and Acquisitions

Medtronic is also making strategic investments to fuel future growth. The company has committed $80 million to Pi-Cardia, a heart-valve repair device maker, with an option to acquire it for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device outside the U.S.

CEO Geoff Martha highlighted the complementary nature of Cornerstone's Sentire system with Medtronic's existing Hugo device, emphasizing the potential for growth in underpenetrated markets such as soft tissue robotic surgery, particularly in emerging regions.

Market Dynamics and Future Outlook

The broader medtech industry is experiencing a surge in demand for advanced surgical technologies. Medtronic's focus on high-growth segments with large patient pools is a strategic move to capitalize on these trends. The company has been active in mergers and acquisitions, aiming to strengthen its position in burgeoning markets.

Despite the positive financial outlook, Medtronic's finance chief Thierry Pieton noted that recent tariff refunds have not been factored into future projections, suggesting a cautious approach in financial planning.

Medtronic's latest quarterly results exceeded expectations, with an adjusted per-share profit of $1.45 on revenues of $9.76 billion, surpassing forecasts of $1.39 per share on $9.55 billion in sales.